148 related articles for article (PubMed ID: 15686688)
1. Erythrocyte sodium lithium countertransport in renal transplant recipients with mycophenolate mofetil and low-dose cyclosporine.
Vareesangthip K; Hanlakorn P; Suwannaton L; Larpkitkachorn R; Chuawattana D; Pidetcha P; Ong-Aj-Yooth L
Transplant Proc; 2004 Dec; 36(10):3032-5. PubMed ID: 15686688
[TBL] [Abstract][Full Text] [Related]
2. Abnormal kinetics of erythrocyte sodium lithium countertransport in renal transplant recipients.
Vareesangthip K; Hanlakorn P; Suwannaton L; Pidetcha P; Ong-Aj-Yooth L
Transplant Proc; 2004 Jun; 36(5):1367-71. PubMed ID: 15251334
[TBL] [Abstract][Full Text] [Related]
3. Low-dose cyclosporine and mycophenolate mofetil in renal allograft recipients with suboptimal renal function.
Hueso M; Bover J; Serón D; Gil-Vernet S; Sabaté I; Fulladosa X; Ramos R; Coll O; Alsina J; Grinyó JM
Transplantation; 1998 Dec; 66(12):1727-31. PubMed ID: 9884267
[TBL] [Abstract][Full Text] [Related]
4. Early steroid withdrawal protocol with basiliximab, cyclosporine and mycophenolate mofetil in renal-transplant recipients.
Kato Y; Tojimbara T; Iwadoh K; Koyama I; Nanmoku K; Kai K; Sannomiya A; Nakajima I; Fuchinoue S; Teraoka S
Int Immunopharmacol; 2006 Dec; 6(13-14):1984-92. PubMed ID: 17161352
[TBL] [Abstract][Full Text] [Related]
5. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group.
Gruessner RW
Clin Transplant; 1997 Aug; 11(4):299-312. PubMed ID: 9267719
[TBL] [Abstract][Full Text] [Related]
6. Impact of daclizumab, low-dose cyclosporine, mycophenolate mofetil and steroids on renal function after kidney transplantation.
Fangmann J; Arns W; Marti HP; Hauss J; Ketteler M; Beckurts T; Boesmueller C; Pohanka E; Martin PY; Gerhardt M; Farese S; Neumayer HH; Floege J; Gurr C; Budde K;
Nephrol Dial Transplant; 2010 Jan; 25(1):283-92. PubMed ID: 19773417
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of low-dose mycophenolate mofetil therapy for Taiwanese renal transplantation patients receiving primary cyclosporine immunosuppression.
Tsai MK; Hu RH; Lee CJ; Lee PH
J Formos Med Assoc; 2002 Sep; 101(9):616-21. PubMed ID: 12645188
[TBL] [Abstract][Full Text] [Related]
8. Improvement of impaired renal function in heart transplant recipients treated with mycophenolate mofetil and low-dose cyclosporine.
Aleksic I; Baryalei M; Busch T; Pieske B; Schorn B; Strauch J; Sîrbu H; Dalichau H
Transplantation; 2000 Apr; 69(8):1586-90. PubMed ID: 10836367
[TBL] [Abstract][Full Text] [Related]
9. Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen: results of a five-year, prospective, randomized study.
Abramowicz D; Del Carmen Rial M; Vitko S; del Castillo D; Manas D; Lao M; Gafner N; Wijngaard P;
J Am Soc Nephrol; 2005 Jul; 16(7):2234-40. PubMed ID: 15917338
[TBL] [Abstract][Full Text] [Related]
10. Low-dose versus high-dose cyclosporine induction protocols in renal transplantation.
Ghafari A; Makhdoomi K; Ahmadpour P; Afshari AT; Fallah MM; Rad PS
Transplant Proc; 2007 May; 39(4):1219-22. PubMed ID: 17524937
[TBL] [Abstract][Full Text] [Related]
11. Mycophenolate mofetil, an alternative to cyclosporine A for long-term immunosuppression in kidney transplantation?
Houde I; Isenring P; Boucher D; Noël R; Lachanche JG
Transplantation; 2000 Oct; 70(8):1251-3. PubMed ID: 11063351
[TBL] [Abstract][Full Text] [Related]
12. Successful withdrawal of steroids in pediatric renal transplant recipients receiving cyclosporine A and mycophenolate mofetil treatment: results after four years.
Höcker B; John U; Plank C; Wühl E; Weber LT; Misselwitz J; Rascher W; Mehls O; Tönshoff B
Transplantation; 2004 Jul; 78(2):228-34. PubMed ID: 15280683
[TBL] [Abstract][Full Text] [Related]
13. Graft survival following living-donor renal transplantation: a comparison of tacrolimus and cyclosporine microemulsion with mycophenolate mofetil and steroids.
Bunnapradist S; Daswani A; Takemoto SK
Transplantation; 2003 Jul; 76(1):10-5. PubMed ID: 12865780
[TBL] [Abstract][Full Text] [Related]
14. Abnormal kinetics of erythrocyte Na/Li countertransport in renal transplant patients treated with cyclosporine.
Vareesangthip K; Nimmannit S; Vanichakarn S; Pidetcha P; Suwannaton L; Ong-Aj-Yooth L
Transplant Proc; 2000 Nov; 32(7):1857-8. PubMed ID: 11119971
[No Abstract] [Full Text] [Related]
15. Mycophenolate mofetil substitution for cyclosporine a in renal transplant recipients with chronic progressive allograft dysfunction: the "creeping creatinine" study.
Dudley C; Pohanka E; Riad H; Dedochova J; Wijngaard P; Sutter C; Silva HT;
Transplantation; 2005 Feb; 79(4):466-75. PubMed ID: 15729174
[TBL] [Abstract][Full Text] [Related]
16. Cyclosporin withdrawal with concomitant conversion from azathioprine to mycophenolate mofetil in renal transplant recipients with chronic allograft nephropathy: a 2-year follow-up.
Ducloux D; Motte G; Billerey C; Bresson-Vautrin C; Vautrin P; Rebibou JM; Saint-Hillier Y; Chalopin JM
Transpl Int; 2002 Sep; 15(8):387-92. PubMed ID: 12221456
[TBL] [Abstract][Full Text] [Related]
17. [Use of mycophenolate mofetil in patients with a transplanted kidney and cyclosporin nephrotoxicity].
Hrvacević R; Ignjatović Lj; Vavić N; Dimitrijević J; Drasković-Pavlović B; Dujić A; Elaković D; Kronja G; Marić M
Vojnosanit Pregl; 2001; 58(2):157-60. PubMed ID: 11475669
[TBL] [Abstract][Full Text] [Related]
18. Outcome in cadaveric renal transplant recipients treated with cyclosporine A and mycophenolate mofetil versus cyclosporine A and azathioprine.
Lee CM; Markezich AJ; Scandling JD; Dafoe DC; Alfrey EJ
J Surg Res; 1998 May; 76(2):131-6. PubMed ID: 9698512
[TBL] [Abstract][Full Text] [Related]
19. A randomized long-term trial of tacrolimus and sirolimus versus tacrolimus and mycophenolate mofetil versus cyclosporine (NEORAL) and sirolimus in renal transplantation. I. Drug interactions and rejection at one year.
Ciancio G; Burke GW; Gaynor JJ; Mattiazzi A; Roth D; Kupin W; Nicolas M; Ruiz P; Rosen A; Miller J
Transplantation; 2004 Jan; 77(2):244-51. PubMed ID: 14742989
[TBL] [Abstract][Full Text] [Related]
20. Mycophenolate mofetil, with cyclosporine and prednisone, reduces early rejection while allowing the use of less antilymphocytic agent induction and cyclosporine in renal recipients with delayed graft function.
Arnold AN; Wombolt DG; Whelan TV; Chidester PD; Restaino I; Gelpi B; Stewart M; Hurwitz RL; McCune TR
Clin Transplant; 2000 Aug; 14(4 Pt 2):421-6. PubMed ID: 10946782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
